Open AccessSustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants
Author(s) -
IChin Wu,
Mitchell L. Shiffman,
Myron J. Tong,
Patrick Marcellin,
Elsa Mondou,
David Frederick,
Andrea SnowLampart,
J. Sorbel,
Franck Rousseau,
TingTsung Chang
Publication year - 2008
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/592570
Subject(s) - adefovir , seroconversion , medicine , hbeag , hepatitis b virus , gastroenterology , virology , hepatitis b , virus , lamivudine , hbsag
This study evaluated the persistence of hepatitis B e antigen (HBeAg) seroconversion (which is considered to be an important therapeutic end point) after adefovir dipivoxil treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom